Immunomedics (IMMU) Earns Coverage Optimism Score of 0.10
Headlines about Immunomedics (NASDAQ:IMMU) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Immunomedics earned a news impact score of 0.10 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5327625147216 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have impacted Accern’s analysis:
- Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU) (americanbankingnews.com)
- Immunomedics (IMMU) Price Target Raised to $27.00 (americanbankingnews.com)
- BidaskClub Upgrades Immunomedics (IMMU) to Strong-Buy (americanbankingnews.com)
- Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU) (americanbankingnews.com)
Immunomedics (NASDAQ:IMMU) opened at $16.25 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29. Immunomedics has a fifty-two week low of $4.08 and a fifty-two week high of $18.93. The stock has a market cap of $2,410.00, a price-to-earnings ratio of -7.25 and a beta of 1.50.
Several brokerages recently issued reports on IMMU. Jefferies Group raised their target price on shares of Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 25th. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a report on Friday. Finally, Zacks Investment Research cut shares of Immunomedics from a “buy” rating to a “hold” rating in a report on Wednesday, November 15th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Immunomedics currently has a consensus rating of “Buy” and a consensus target price of $19.00.
In other news, insider Behzad Aghazadeh purchased 1,325,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were bought at an average price of $10.47 per share, for a total transaction of $13,872,750.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Venbio Select Advisor Llc purchased 1,150,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were purchased at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is currently owned by company insiders.
Immunomedics Company Profile
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.